Limitations of C2 monitoring in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 20, Issue 7, 2005, Pages 1463-1470

  Einecke, Gunilla ^a,c   Schütz, Manuela ^a   Mai, Ingrid ^b   Fritsche, Lutz ^a   Giessing, Markus ^a   Glander, Petra ^a   Neumayer, Hans H ^a   Budde, Klemens ^a  

^a Department of Nephrology ^*  (Germany)

^b Institute for Clinical Pharmacology   (Germany)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

C2monitoring; Cyclosporin; Immunosuppression; Pharmacokinetics; Renal transplant patients

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MALE; MICROEMULSION; MULTICENTER STUDY; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CHEMICALLY INDUCED DISORDER; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY DISEASE; MIDDLE AGED; PHYSIOLOGY; PREDICTION AND FORECASTING; TIME; VALIDATION STUDY;

ADULT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 26044441913     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh819     Document Type: Article

References (20)

1. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998; 12: 243-249
2. Keown P, Landsberg D, Halloran P et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996; 62: 1744-1752
3. Keown P, Cole E, Landsberg D et al. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024-1032
4. Keown PA, Cole E, Muirhead N et al. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157-166
5. Cole E, Naham N, Cardella C et al. Clinical benefits of Neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 2003; 75: 2086-2090
6. Thervet E, Pfeffer P, Scolari MP et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C-2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903-908
7. Maham N, Cardella C, Cattran D et al. Optimization of cyclosporine exposure utilizing C-2 level monitoring in de novo renal transplant recipients: The Toronto General Hospital experience. Transplant Proc 2001; 33: 3098-3099
8. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Recommendations for the implementation of Neoral C-2 monitoring in clinical practice. Transplantation 2002; 73: S19-S22
9. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C-2 monitoring: An international consensus statement. Transplantation 2002; 73: S12-S18
10. Budde K, Glander P, Diekmann F et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333-1345
11. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 2001; 12: 828-833
12. Balbontin F, Kiberd B, Singh D et al. Basiliximab widens the therapeutic window for AUC-monitored Neoral therapy early after kidney transplantation. Transplant Proc 2003; 35: 2409-2411
13. Nashan B, Armstrong VW, Budde K et al. Cyclosporine C2-monitoring for optimisation of immunosuppression in renal transplantation - recommendations according to first experiences in German centers. Transplantationsmedizin 2003; 15: 15-24
14. Felipe CR, Silva HT, Machado PGP, Garcia R, Moreira SRD, Pestana JOM. Time-dependent changes in cyclosporine exposure: Implications for achieving target concentrations. Transplant Int 2003; 16: 494-503
15. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: A population analysis in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 651-660
16. Veau C, Leroy C, Banide H et al. Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 2001; 16: 1607-1614
17. Talaulikar GS, John GT, Selvakumar R, Job V, Thomas PP, Jacob CK. Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. Transplant Proc 2003; 35: 1295-1297
18. Lown KS, Mayo RR, Leichtman AB et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260
19. Brunner LJ, Bennett WM, Keep DR. Cyclosporine suppresses rat hepatic cytochrome P450 in a time-dependent manner. Kidney Int 1998; 54: 216-223
20. Morales J, Buckel E, Fierro A, Zehnder C, Herzog C, Manalich J. A simple method to calculate cyclosporine dosage to obtain a target C2 drug level. Ther Drug Monitor 2003; 25: 389-392